Research ArticlePatient Safety
Open Access
Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration
E. Kanal, T.J. Patton, I. Krefting and C. Wang
American Journal of Neuroradiology March 2020, 41 (3) 393-399; DOI: https://doi.org/10.3174/ajnr.A6448
E. Kanal
aDepartments of Radiology (E.K.)
T.J. Patton
bDermatology (T.J.P.), University of Pittsburgh Medical Center and University of Pittsburgh, Pittsburgh, Pennsylvania
I. Krefting
cDivision of Medical Imaging and Radiation Medicine (I.K.)
C. Wang
dOffice of Pharmacovigilance and Epidemiology (C.W.), US Food and Drug Administration, Silver Spring, Maryland.

Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
American Journal of Neuroradiology
Vol. 41, Issue 3
1 Mar 2020
Advertisement
E. Kanal, T.J. Patton, I. Krefting, C. Wang
Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration
American Journal of Neuroradiology Mar 2020, 41 (3) 393-399; DOI: 10.3174/ajnr.A6448
Jump to section
Related Articles
- No related articles found.
Cited By...
This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.
More in this TOC Section
Similar Articles
Advertisement